Prediction of Drug Distribution in Subcutaneous Xenografts of Human Tumor Cell Lines and Healthy Tissues in Mouse: Application of the Tissue Composition-Based Model to Antineoplastic Drugs

Journal of Pharmaceutical Sciences

Volumn 104, Issue 4, 2015, Pages 1508-1521

  Poulin, Patrick ^a   Chen, Yung Hsiang ^b   Ding, Xiao ^b   Gould, Stephen E ^b   Hop, Cornelis Eca ^b   Messick, Kirsten ^b   Oeh, Jason ^b   Liederer, Bianca M ^b  

^a Genentech Inc ^*  (Canada)

^b GENENTECH INC   (United States)

Author keywords

ADME; chemotherapy; disposition; distribution; oncology; partition coefficients; PBPK modeling; pharmacokinetics; tumor; xenograft

Indexed keywords

DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; TOPOTECAN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG LUNG LEVEL; DRUG MUSCLE LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; MOUSE; NONHUMAN; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; COLON TUMOR; DOG; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MDCK CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DOGS; FEMALE; HCT116 CELLS; HETEROGRAFTS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE, NUDE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 84924764453     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24336     Document Type: Article

References (62)

1. Tarique I, Venkateshan SP, Tandon M, Nilanjan S, Pillai KK. 2011. Comparative evaluation of US Food and Drug Administration and pharmacologically guided approaches to determine the maximum recommended starting dose for first-in-human clinical trials in adult healthy men. Clin Pharmacol 51:1655-1664.
2. Mariappan TT, Mandlekar S, Marathe P. 2013. Insight into tissue unbound concentration: Utility in drug discovery and development. Curr Drug Metab 14:324-340.
3. Poulin P, Hop ECA, Salphalti L, Liederer B. 2013. Correlation of tissue:plasma partition coefficient between healthy tissues and subcutaneous xenografts of human tumor cell lines in mouse as a prediction tool of drug penetration in tumors. J Pharm Sci 102:1355-1369.
4. Poulin P, Dambach DM, Hartley DH, Ford K, Theil FP, Harstad E, Halladay J, Choo E, Boggs K, Liederer BM, Dean B, Diaz D. 2013. An algorithm for evaluating potential tissue drug distribution in toxicology studies from readily available pharmacokinetic parameters. J Pharm Sci 102:3816-3829.
5. Haritova AM, Fink-Gremmels J. 2010. A simulation model for the prediction of tissue:plasma partition coefficients for drug residues in natural casings. The Vet J 185:278-284.
6. Richter W, Starke V, Whitby B. 2006. The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies. Eur J Pharm Sci 28:155-165.
7. Poulin P, Theil FP. 2000. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically based pharmacokinetic models in drug discovery. J Pharm Sci 89:16-35.
8. Poulin, P, Theil FP. 2009. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98:4941-4961.
9. Poulin P, Ekin, S, Theil FP. 2011. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 250:194-212.
10. Björkman S. 2002. Prediction of the volume of distribution of a drug: Which tissue:plasma partition coefficients are needed? J Pharm Pharmacol 54:1237-1245.
11. Jansson R, Bredberg U, Ashton M. 2008. Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 97:2324-2339.
12. Edginton AN, Yun YE. 2013. Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. Xenobiotica 43:839-852.
13. Yoshida M, Kobunai T, Aoyagi K, Saito H, Utsugi T, Wierzba K, Yamada Y. 2000. Specific distribution of TOP-53 to the lung and lunglocalized tumor is determined by its interaction with phospholipids. Clin Cancer Res 6:4396-4401.
14. Yata N, Toyoda T, Murakami T, Nishura A, Higashi Y. 1999. Phosphatidylserine for the tissue distribution of weakly basic drugs in rats. Pharm Res 7:1019-1025.
15. Peyret T, Poulin P, Krishnan K. 2011. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol 249:197-207.
16. Rodgers T, Rowland M. 2006. Physiologically-based pharmacokinetics modeling 2: Predicting the t issue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1252.
17. Mairinger S, Erker T, Müller M, Langer O. 2011. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab 12:774-792.
18. Hudachek S, Gustafson DL. 2013. Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. J Pharmacokinet Pharmacodyn 40:437-449.
19. Martignoni M, de Kanter R, Moscone A, Grossi P, Monshouwer M. 2005. Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice. Cancer Chemother Pharmacol 55:129-135.
20. Drug bank. Assessed June 22, 2014, at: http://www.drugbank.ca/drugs.
21. th 2013. Uxbridge, Middlesex, UK: GlaxoSmithKline, UB11 1BT.
22. Bradshaw-Pierce EL, Eckhardt SG, Gustafson D. 2007. A physiologically-based pharmacokinetic model of Docetaxel disposition: From mouse to man. Clin Res Cancer 13:2768-2776.
23. Mosure KW, Henderson AJ, Klunk LW, KNipe JO. 1997. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemother Pharmacol 40:251-258.
24. Sani SN, Henry K, Boehlke JK, Stricker-Krongrad A, Maher TJ. 2010. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in healthy and tumorbearing mice: A microdialysis study. Cancer Chemother Pharmacol 66:159-169.
25. Shah DK, Balthasar JP. 2011. Physiologically-based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn 38:121-142.
26. Beumer JH, Eiseman JL, Parise RA. 2008. Modulation of Gemcitabine (2,2-difluoro-2-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res 14:3529-3535.
27. Homan R, Anderson MK. 1998. Rapid separation and quantification of combined neutral and polar lipid classes by high-performance liquid chromatography and evaporative light-scattering mass detection. J Chromatogr B 708:21-26.
28. Prasad B, Evers R, Gupta A, Hop ECA, Salphati L, Shukla S, Ambudkar S, Unadkat JD. 2014. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: Quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos 42:78-88.
29. Huxham LA, Kyle AH, Baker JHE, et al. 2004. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 64:6537-6541.
30. Ojugol ASE, McSheehy PMJ, Stubbs M, Alder G, Bashford CL, Maxwell RJ, Leach MO, Judson IR, Griffiths GR. 1998. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer 77:873-879.
31. Lyng H, Tufto I, Skretting A, Rofstad EK. 1997. Proton relaxation times and interstitial fluid pressure in human melanoma xenografts. Br J Cancer 75:180-183.
32. Berk DA, Yuan F, Leunig M, Rakesh KJ. 1997. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci USA 94:1785-1790.
33. Boswell AC, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA. 2011. Effects of Anti-VEGF on predicted antibody biodistribution: Roles of vascular volume, interstitial volume, and blood flow. PLoS One 6:e17874.
34. Raghunand N, Altbach MI, Van Sluis R, Baggett B. 1999. Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 57:309-312.
35. Calderwood SK, Dickson JA. 1980. Effect of hyperglycemia on blood flow, pH, and response to hyperthermia of the yoshida sarcoma in the rat. Cancer Res 40:4728-4733.
36. Gerweck LE, Seetharaman K. 1996. Cellular pH gradient in tumors versus healthy tissues: Potential exploitation for the treatment of cancer. Cancer Res 56:1194-1198.
37. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y. 2001. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: Comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. Biopharm Drug Dispos 22:1-14.
38. Thurber GM, Weissleder R. 2011. A systems approach for tumor pharmacokinetics. PLoS One 6:e24696.
39. Huang Y, Sadée W. 2006. Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett 239:168-182.
40. Scotto KW. 2003. Transcriptional regulation of ABC drug transporters. Oncogene 22:7496-7511.
41. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. 2003. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138:1367-1375.
42. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ. 2013. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: The ITC evidence-based position. Nature 94:80-94.
43. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. 2011. Blood-brain barrier (BBB) pharmacoproteomics: Reconstruction of in vivo brain distribution of 11 P-Glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579-588.
44. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. 2011. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-gp, Bcrp, and P-gp/Bcrp knockout mice. Drug Metab Dispos 40:1164-1169.
45. Bleasby K1, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG. 2006. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica 36:963-988.
46. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. 2013. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine 9:111-121.
47. Davis JR, Fernandes C, Zalcberg JR. 1999. Gemcitabine and the blood brain barrier. Aust NZ J Med 6:831-832.
48. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. 2000. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 4:679-686.
49. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. 2009. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: A microdialysis study. J Neurooncol 91:51-58.
50. Zhuang Y, Fraga CH, Elaine KH, Hagedorn N, Panetta JC. Et al. 2006. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 66:23-33.
51. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Emily H, Palmieri D, Polli, et al. 2012. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770-781.
52. Lv H, Zhang X, Sharma J, Reddy MVR, Reddy EP, Gallo JM. 2012. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J 15:250-257.
53. Zlatopolskiy BD, Morgenroth A, Kunkel FH, Urusova EA, Dinger C, Kull T, Lepping C, Reske SN. 2009. Synthesis and biologic study of IV-14, a new ribonucleoside radiotracer for tumor visualization. J Nucl Med 50:1895-1903.
54. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. 2001. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 26:951-959.
55. Cottin S, Ghani K, Campos-Lima OP, Caruso M. 2010. Gemcitabine intercellular diffusion mediated by gap junctions: New implications for cancer therapy. Mol Cancer 9:141.
56. Tannock Ian F, Lee Carol M, Tunggal Jonathon K et al. 2002. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8:878-884.
57. Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PWK. 2013. Gemcitabine-mediated tumour regression and p53-dependent gene expression: Implications for colon and pancreatic cancer therapy. Cell Death Dis 4:e791.
58. Goricar K, Kovac V, Dolzan V. 2014. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol 48:163-172.
59. Hanumegowda UM, Wenke G, Regueiro-Ren A, Yordanova R, Corradi JP, Adams SP. 2010. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution. Chem Res Toxicol 23:749-755.
60. Lullmann H, Rossen E, Seiler KU. 1972. The pharmacokinetics of phentermine and chlorphentermine in chronically treated rats. J Pharm Pharmacol 25:239-243.
61. Wong H, Choo EF, Alicke B, et al. 2012. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18:3846-3855.
62. Rodgers T, Jones HM, Rowland M. 2012. Tissue lipids and drug distribution: Dog versus rat. J Pharm Sci 101:4615-4625.